Sign up Australia
Proactive Investors - Run By Investors For Investors

Sienna Cancer Diagnostics achieves first sale of cancer test in Switzerland

The company’s in-vitro diagnostic test help urologists detect bladder cancer earlier.
cancer cells
Sienna listed on the ASX in 2017 after raising $4.6 million

Sienna Cancer Diagnostics Ltd (ASX:SDX) has achieved the first sale of its hTERT cancer test in Switzerland through its distribution partner, Biosystems Switzerland AG.

The company’s in-vitro diagnostic (IVD) hTERT test help urologists to detect bladder cancer earlier.

Sienna’s primary platform is the detection of the biomarker telomerase, which is found in nearly all epithelial cancers, and was the subject of a Nobel Prize in 2009.

Telomerase is well recognised as a remarkable biomarker used by 85% of cancers to enable immortal cell replication.

Clinical validation completed by the customer

Following the signing of Biosystems Switzerland as the exclusive distributor for Switzerland of Sienna’s novel IVD test, the first order by a Swiss laboratory has been delivered.

This follows training of Biosystems key personnel by Sienna in late 2017, and evaluation and clinical validation by the customer.

A biomarker test for diagnosing bladder cancer

Although urine cytology is non-invasive, it has significant limitations in terms of sensitivity, particularly when it comes to low-grade or early-stage bladder cancer.

Having a biomarker test that can provide additional clinically significant information for the diagnosing physician, while using the same urine sample collected for cytology, adds real value to the diagnostic process.

Biosystems Switzerland has generated a pipeline of interested laboratories, several of which are well advanced in evaluating the test for clinical use.

READ: Sienna Cancer Diagnostics to launch its in-vitro test in Denmark and Sweden

Sienna listed on the ASX in 2017 following a successful initial public offer (IPO) which raised $4.6 million.

The company achieved significant milestones in 2017, including FDA registration of its IVD product in the U.S. and CE Mark approval and IVD registration in the Europe Union.

Sienna’s near-term objective is to maximise growth opportunities in the U.S., with significant interest already shown by pathology laboratories in the hTERT test.

View full SDX profile View Profile

Sienna Cancer Diagnostics Ltd Timeline

Related Articles

surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
Laboratory
June 21 2018
Genedrive has signed sales agreement with Sysmex Corporation for the distribution of the HCV ID to EMEA and Asia Pacific and with Mumbai- based ARKRAY to distribute the kit in India
People working in a laboratory
May 02 2018
The benefits of Admedus' proprietary ADAPT technology and products are now scientifically proven beyond doubt.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use